COVID-19: We are currently offering vaccinations to current qualifying patients. CURRENT PATIENTS VACCINATION INFO.

Clinical Category: CLL/SLL

A Phase I，Multicenter, Open-Label, Dose Escalation Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell Malignancies
Monika Chaudhry | June 19, 2021

MK1026-003
Monika Chaudhry | April 4, 2021